Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
05/2003
05/30/2003WO2003043583A2 Treatment of immunological disorders using anti-cd30 antibodies
05/30/2003WO2003043580A2 Methods for identifying and validating potential drug targets
05/30/2003WO2003043574A2 Pharmaceutical compositions in particulate form
05/30/2003WO2003026691A3 Use of hmgb1 for the activation of dendritic cells
05/30/2003WO2003016917A3 Sodium channel regulators and modulators
05/30/2003WO2003008448A3 Novel human proton-gated channels
05/30/2003WO2002100328A3 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
05/30/2003WO2002097059A3 Chromosome-based platforms
05/30/2003WO2002064790A3 Jfy1 protein induces rapid apoptosis
05/30/2003WO2002064621A3 Histidine proline rich glycoprotein (hprg) as an anti-angiogenic and anti-tumor agent
05/30/2003WO2002053728A9 Gene disruption methodologies for drug target discovery
05/30/2003WO2002051868A3 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
05/30/2003WO2002048372A3 Target enzymes
05/30/2003WO2002047717A9 Targeted enzyme prodrug therapy
05/30/2003WO2002034291A3 Compositions and methods for treating hematologic malignancies and multiple drug resistance
05/30/2003WO2002031025A9 Biodegradable poly(beta-amino esters) and uses thereof
05/30/2003WO2002000692A9 Pd-l2 molecules: pd-1 ligands and uses therefor
05/30/2003WO2001092542A3 Integrin-targeting vectors having enhanced transfection activity
05/30/2003WO2001052874A9 Intra-tumoral administration of il-12 encoding nucleic acid molecules
05/30/2003CA2468107A1 Methods for identifying and validating potential drug targets
05/30/2003CA2467930A1 Treatment of pml targeting jc virus agno
05/30/2003CA2467915A1 Compositions inhibiting rejection in organ transplantation and method of using the same
05/30/2003CA2467908A1 Mfg-e8-l regulates phagocytic removal of apoptotic cells by macrophages
05/30/2003CA2467242A1 Treatment of immunological disorders using anti-cd30 antibodies
05/30/2003CA2467206A1 Genes encoding g-protein coupled receptors and methods of use therefor
05/30/2003CA2466982A1 Pharmaceutical compositions in particulate form
05/30/2003CA2464542A1 Composition comprising and method of using angiopoietin-like protein 3 angptl3
05/30/2003CA2463790A1 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use
05/30/2003CA2411208A1 Vector encoding suicide and marker constructs
05/30/2003CA2407302A1 Genes transfection into bony tissues
05/29/2003US20030101480 Artificial chromosomes, uses therof and methods for preparing artificial chromosomes
05/29/2003US20030101472 Generation of genetically engineered cells using retroviral vector; for use in generation of disease models
05/29/2003US20030101471 Method for producing transgenic birds and fish
05/29/2003US20030101466 Method for screening for agents against cancer using an immunosuppression animal model
05/29/2003US20030100530 Thyroid stimulating hormone sensitive cell that overexpresses pituitary tumor transforming gene in response to thyroid stimulating hormone
05/29/2003US20030100526 Operably linked mammalian muscle creatine kinase promoter, mammalian desmin promoter and enhancers thereof, and vertebrate troponin I IRE enhancer; gene therapy
05/29/2003US20030100525 Amino acid sequences; anticaner agents, monitoring, diagnosis
05/29/2003US20030100520 Immunizing mammal with inoculum containing a vehicle in which is dissolved or dispersed recombinant DNA molecule; maintaining immunized mammal for a time period for production of antibodies that bind to cholesteryl ester transfer protein
05/29/2003US20030100503 Neurogenic compositions and methods
05/29/2003US20030100496 Compositions and methods for highly efficient transfection
05/29/2003US20030100488 Osteoprotegerin binding proteins
05/29/2003US20030100116 Canine adenovirus vectors for the transfer of genes in targeted cells
05/29/2003US20030100115 Killing cells that lack tumor suppressor proteins; obtain cells, transform with preferential single stranded nucleotide sequence, monitor viability of cells
05/29/2003US20030100113 Plasmids for use in the transfer of nucleotide sequences into cells
05/29/2003US20030100093 Human telomerase catalytic subunit: diagnostic and therapeutic methods
05/29/2003US20030100058 Nucleotide sequences coding polypeptide for use in the treatment of cell proliferative disorders
05/29/2003US20030100049 AKT nucleic acids, polypeptides, and uses thereof
05/29/2003US20030100026 Stimulus-inducible protein kinase complex and methods of use therefor
05/29/2003US20030099994 Novel FDRG protein and nucleic acid molecules and uses therefor
05/29/2003US20030099991 Detection of nucleotide sequences associated pain and nervous system disorders; obtain sample, incubate with probe, detect signal, recover nucleic acid, incubate with primer, amplify, evaluate for disorder
05/29/2003US20030099982 Regulation of human glur5 -like receptor
05/29/2003US20030099978 Application of aprataxin gene to diagnosis and treatment for early-onset spinocerebellar ataxia (EAOH)
05/29/2003US20030099971 Epidermal differentiation factor
05/29/2003US20030099963 Nucleotied sequences coding polypeptide for use in the diagnosis and treatment of cancer
05/29/2003US20030099959 Cooperative oligonucleotides
05/29/2003US20030099687 Combination for the treatment of endothelial damage
05/29/2003US20030099671 Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies and gene therapy in the CNS
05/29/2003US20030099670 Comprises RNA-sequence encoding modified RNA-polymerase due to wild-type point mutations apy; genetic engineering; immunotherapy
05/29/2003US20030099662 Proteins
05/29/2003US20030099660 For regenerating tissues; antiaging agents; medical diagnosis; monitoring chemotherapy
05/29/2003US20030099654 Comprises antibodies/proteins providing inhibition of prothrombinase; treatment and prevention of bacterial and viral infections, allograft/xenograft rejection, glomerulo-nephritis, cancer, gastrointestinal diseases, and fetal loss
05/29/2003US20030099653 Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity
05/29/2003US20030099643 Methods for selectively stimulating proliferation of t cells
05/29/2003US20030099631 A metalloprotease having a proteolytic activity; treating various diseases such as diabetic nephropathy, glomerulonephritis, fibrosis, cirrhosis, osteopetrosis and herniated disk; drug screening kits
05/29/2003US20030099628 Preventing proliferation of a tumor, using heparinase III; use sequencing heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis
05/29/2003US20030099627 Method for determining modulation of p110delta activity
05/29/2003US20030099621 Screening cells to identify stem cells having a beneficial gene, and transplanting the cells into a patient to treat HIV or AIDS
05/29/2003US20030099619 Method and composition for targeting an adenoviral vector
05/29/2003US20030099618 Administering a genetic engineered virus virions, comprising a nucleotide sequence able to code antihemophilic factor protein; patient's blood will able to clot
05/29/2003US20030099617 Method for using thymosin beta-10 for gene therapy of solid malignant tumors
05/29/2003US20030099616 Synergistically targeting the malignant cells, transduction of the vector into a mammalian cell, gene expressing telomerase reverse transcriptase causes killing of the cancer cell; genetic engineering
05/29/2003US20030099615 Porcine adenovirus E1 and E4 regions
05/29/2003US20030099614 2-Methoxyestradiol-induced apoptosis in cancer cells
05/29/2003US20030099613 An encoded repressor or activator and a viral nucleotide sequence for replication; preparing a vaccine for the prophylaxis of AIDS, human immunodeficiency virus
05/29/2003US20030099611 Manipulation and detection of protein phosphatase 2c-pp2calpha - expression in tumor cells for cancer therapy, prevention and detection
05/29/2003US20030099609 Canine IL-4 nucleic acid molecules and uses thereof
05/28/2003EP1314784A1 G-protein coupled receptor LUSTR2 and uses thereof
05/28/2003EP1313885A2 Methods of using agents that modulate bone formation and inhibit adipogenesis
05/28/2003EP1313882A2 Diagnosis and treatment of prostate cancer
05/28/2003EP1313855A2 Truncated bard1 protein, and its diagnostic and therapeutic uses
05/28/2003EP1313853A2 Modulation of fas and fasl expression
05/28/2003EP1313772A1 New cross-linked derivatives of hyaluronic acid
05/28/2003EP1313768A2 Antisense oligonucleotides against vr1
05/28/2003EP1313762A2 Suppressor gene
05/28/2003EP1313761A1 18 human secreted proteins
05/28/2003EP1313753A2 Regulator gene and system useful for the diagnosis and therapy of osteoporosis
05/28/2003EP1313514A2 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
05/28/2003EP1313512A1 Vascular endothelial growth factor 2
05/28/2003EP1313501A2 Functions for dp214
05/28/2003EP1313476A2 Sgk2 and sgk3 used as diagnostic and therapeutic targets
05/28/2003EP1200112B1 Chemokine binding protein of gammaherpesvirus 68 and methods of use therefor
05/28/2003EP1032429B1 A method for in vivo dna delivery using a needle free apparatus
05/28/2003EP0968227B1 Dimeric cationic lipids on dicystine basis
05/28/2003EP0871457B1 Isolated stromal cells and methods of using the same
05/28/2003EP0830604B1 Uses of apoptin
05/28/2003CN1420934A Targeted artificial gene delivery
05/28/2003CN1420933A Method of inducing angiogenesis by micro-organs
05/28/2003CN1420924A Recombinant human alpha-L-iduronidase, method for producing and purifying same and method for treating disorders including deficiency thereof
05/28/2003CN1420785A Method of treating cancer with anti-neurotrophin agents
05/28/2003CN1420783A Compositions and methods for tumor-targeted delivery of effector molecules
1 ... 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 ... 870